Autres langues CASI Pharmaceuticals, Inc. Nasdaq

Actions

Marché Fermé - Nasdaq 21:40:13 02/09/2026			Varia. 5j.	Varia. 1 janv.
0,1350 ^USD	+4,81%		0,00%	-84,12%

14/08	CASI Pharmaceuticals, Inc. publie ses résultats pour le premier semestre clos le 30 juin 2026	CI
13/08	Casi Pharmaceuticals, Inc. annonce des changements au sein de sa direction	CI

14/08	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026
14/08	CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results
13/08	Casi Pharmaceuticals, Inc. Announces Management Changes
01/07	CASI Pharmaceuticals : Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Active and Chronic Active Antibody-mediated Rejection
02/06	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026
15/05	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
15/05	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
20/04	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP
20/04	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026
03/03	CASI Pharmaceuticals, Inc. Announces CEO Changes
03/03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026